By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them. You can change your Cookie Settings at any time but parts of our site will not function correctly without them.

Reject
United Kingdom | EnglishEN

Current country and language: United KingdomUnited Kingdom | English (EN)

ChinaChina
GermanyGermany
IrelandIreland
ItalyItaly
SpainSpain
United KingdomUnited Kingdom

YOU ARE LEAVING THE CURRENT LANGUAGE


Nizoral Acquisition in APAC and Proposed Placing

19th Jun 2018
Alliance Pharma plc 
("Alliance" or the "Group")
Acquisition of Nizoral in Asia-Pacific 
Proposed Equity Placing to raise £34.0 million

 
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, is pleased to announce that it has agreed to acquire exclusive marketing rights to Nizoral, a medical, anti-dandruff shampoo brand, in Asia-Pacific ("APAC") (the "Nizoral Rights") from Janssen Pharmaceutica NV (a member of the Johnson & Johnson group of companies) (the "Vendor") for a total consideration of £60.0 million (the "Acquisition"). 

The Acquisition, which will boost Alliance's successful and rapidly growing APAC distributor business, is expected to generate material earnings enhancement in the first full year of ownership. 

The Acquisition will be funded by an underwritten equity placing of new ordinary shares in the capital of the Company to raise gross proceeds of £34.0 million (c. £32.1 million net of transaction expenses) (the "Placing") at an indicative placing price of 91 pence per Placing Share, to be confirmed pursuant to an accelerated bookbuild process, and by the draw down of c.£27.9 million of a £35.0 million extension of the Group's debt facilities. The Placing is being conducted by means of an accelerated bookbuild process, which will be launched immediately following this announcement.

Transaction highlights 
  • Alliance has agreed to acquire Nizoral, a medical, anti-dandruff shampoo brand, in the APAC region from Janssen Pharmaceutica NV for a total consideration of £60 million payable to the Vendor on completion
  • The consideration will be funded by a combination of the underwritten Placing to raise net proceeds of c.£32.1 million and c.£27.9 million in debt
  • The Nizoral Rights include more than 15 countries including Japan, Thailand, South Korea, China and Pacific markets 
  • In 2017, the Nizoral Rights achieved net sales of £18.5 million1 in APAC
  • Taking into account Alliance's anticipated costs, the Nizoral Rights would have generated EBITDA on a pro forma basis in APAC ("Pro Forma EBITDA") of £7.1 million in 2017
  • The Acquisition boosts Alliance's exposure to fast-growing APAC markets and will enhance Alliance's APAC distributor footprint
  • Nizoral will represent Alliance's fourth International Star brand, complementing Kelo-cote™, MacuShield™ and Vamousse™  
  • The Acquisition is expected to generate material earnings enhancement in the first full year of ownership 
  1 Currency conversion rate: £1.00 = USD1.3528
 
Peter Butterfield, Chief Executive Officer of Alliance, commented:
 
"Asia-Pacific is Alliance's fastest-growing region and we are delighted to strengthen the development of our APAC business through this earnings-enhancing acquisition of Nizoral, an excellent brand with a long medical heritage. Nizoral has significant sales, profits and growth potential in the APAC region and will become the fourth International Star brand in our product portfolio." 
 
For further information:
 

Alliance Pharma plc                                                                Tel:  +44 (0) 1249 466 966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
 
Numis Securities Limited                                                       Tel:  +44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield / Freddie Naylor-Leyland 
Corporate Broking: James Black 
 
Investec Bank plc                                                                    Tel:  +44 (0) 20 7597 5970
Corporate Finance: Daniel Adams
Corporate Broking: Patrick Robb / David Herring
 
Buchanan                                                                                 Tel:  +44 (0) 20 7466 5000
Mark Court / Sophie Wills / Gemma Mostyn-Owen
alliancepharma@buchanan.uk.com  
 
 
Conference Call
Peter Butterfield, CEO, Andrew Franklin, CFO, and Alex Duggan, CCO, will present details of the Acquisition and Placing during a conference call for analysts and investors at 8.30am BST today. A presentation to accompany the conference call will be made available prior to the call on the Group's website at www.alliancepharmaceuticals.com.
 
Conference call details:
Participant dial-in:          +44 (0) 20 3428 1542        
International dial-in:       http://events.arkadin.com/ev/docs/FEL_Events_International_Access_List.pdf
Participant code:             67141876#
                
 Notes to editors
 
Alliance Pharma plc is an international specialty pharmaceutical company.
Headquartered in Chippenham, UK, Alliance commenced trading in 1998 and has been listed on AIM since 2003. Alliance has a strong track record of acquiring established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. It has sales in more than 100 countries either directly via its affiliates or through its selected network of distributor partners. Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
 
  
 
 

By clicking "Yes" below, you hereby confirm that you are not accessing
the information provided on this website from the United States of America.